Trial Profile

Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Obesity
Focus Registrational; Therapeutic Use
Acronyms STEP 6
Sponsors Novo Nordisk

Most Recent Events

30 Nov 2020 Status changed from active, no longer recruiting to completed.
20 Oct 2020 Planned primary completion date changed from 19 Oct 2020 to 20 Nov 2020.
23 Jul 2020 Planned End Date changed from 30 Nov 2020 to 20 Nov 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com